&lt;p&gt;The Perspective of Diagnostic and Prognostic Values of Lipoxygenases mRNA Expression in Colon Adenocarcinoma&lt;/p&gt;

Ruan, Guo‐Tian; Gong, Yizhen; Zhu, Linghua; Gao, Feng; Liao, Xiwen; Wang, Xiangkun; Zhu, Guangzhi; Liao, Cun; Wang, Shuai; Yan, Ling; Xie, Hailun; Zhou, Xin; Liu, Junqi; Shao, Meng-Nan; Gan, Jialiang

doi:10.2147/ott.s251965

Cited by 13 publications

(13 citation statements)

References 69 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ROC curve analysis showed significantly high clinical diagnostic potential of the aforementioned immunoresolvents, particularly of resolvin D1. Therefore, our results support the hypotheses presented by previous studies, which suggest that genetic expression of LOX and/or LOX-derived eicosanoids may be significantly associated with carcinogenesis in addition to being promising biomarkers of various types of solid malignancies ( 34 , 35 ). We emphasize that our results are preliminary considering the small sample size of our study; further large-scale clinical studies are warranted to validate and characterize the diagnostic potential of the aforementioned immunoresolvents in patients with pancreatic cancer.…”

Section: Discussionsupporting

confidence: 92%

Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report

et al. 2022

View full text Add to dashboard Cite

Eicosanoids are bioactive lipids derived from arachidonic acid, which have emerged as key regulators of a wide variety of pathophysiological processes in recent times and are implicated as mediators of gastrointestinal cancer. In this study, we investigated the systemic levels of lipoxygenase (LOX)-derived lipoxin A4 and B4, together with resolvin D1 and D2 in patients with pancreatic adenocarcinoma (n = 68), as well as in healthy individuals (n = 32). Systemic concentrations of the aforementioned immunoresolvents were measured using an enzyme-linked immunosorbent assay (ELISA). In this study, we observed that compared with concentrations in healthy individuals, the peripheral concentrations of the aforementioned eicosanoids were significantly elevated (2- to 10-fold) in patients with pancreatic cancer (in all cases p<0.00001). No significant association was observed between eicosanoid levels and the TNM clinical staging. Furthermore, we observed no significant differences in concentrations of the analyzed bioactive lipids between patients diagnosed with early-stage (TNM stage I-II) and more advanced disease (TNM stage III-IV). Receiver operating characteristic (ROC) curve analysis of each aforementioned immunoresolvent showed area under the curve values ranging between 0.79 and 1.00. Sensitivity, specificity, as well as positive and negative predictive values of the eicosanoids involved in the detection/differentiation of pancreatic adenocarcinoma ranged between 56.8% and 100%. In summary, our research is the first study that provides clinical evidence to support a systemic imbalance in LOX-derived lipoxins and resolvins as the mechanism underlying the pathogenesis of pancreatic adenocarcinoma. This phenomenon occurs regardless of the clinical TNM stage of the disease. Furthermore, our study is the first to preliminarily highlight the role of peripheral levels of immunoresolvents, particularly resolvin D1, as potential novel biomarkers of pancreatic cancer in humans.

show abstract

Section: Discussionsupporting

confidence: 92%

Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For instance, ALOXE3, which encodes arachidonate lipoxygenase3, can serve as a potential predictive biomarker for colon adenocarcinoma patients. Low expression of ALOXE3 had a favorable prognosis of COAD (11). Goḿez-Maldonado et al identified EFNA3, a member of the ephrin type A ligands, is induced by hypoxia-inducible factor in human tumors and this induction is predictive of poor prognosis and increased risk of metastasis in breast cancer patients (12).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma

Tong

Wang

2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCutaneous melanoma (CM) is one of the most aggressive cancers with highly metastatic ability. To make things worse, there are limited effective therapies to treat advanced CM. Our study aimed to investigate new biomarkers for CM prognosis and establish a novel risk score system in CM.MethodsGene expression data of CM from Gene Expression Omnibus (GEO) datasets were downloaded and analyzed to identify differentially expressed genes (DEGs). The overlapped DEGs were then verified for prognosis analysis by univariate and multivariate COX regression in The Cancer Genome Atlas (TCGA) datasets. Based on the gene signature of multiple survival associated DEGs, a risk score model was established, and its prognostic and predictive role was estimated through Kaplan-Meier (K-M) analysis and log-rank test. Furthermore, the correlations between prognosis related genes expression and immune infiltrates were analyzed via Tumor Immune Estimation Resource (TIMER) site.ResultsA total of 103 DEGs were obtained based on GEO cohorts, and four genes were verified in TCGA datasets. Subsequently, four genes (ADAMDEC1, GNLY, HSPA13, and TRIM29) model was developed by univariate and multivariate Cox regression analyses. The K-M plots showed that the high-risk group was associated with shortened survival than that in the low-risk group (P < 0.0001). Multivariate analysis suggested that the model was an independent prognostic factor (high-risk vs. low-risk, HR= 2.06, P < 0.001). Meanwhile, the high-risk group was prone to have larger breslow depth (P< 0.001) and ulceration (P< 0.001).ConclusionsThe four-gene risk score model functions well in predicting the prognosis and treatment response in CM and will be useful for guiding therapeutic strategies for CM patients. Additional clinical trials are needed to verify our findings.

show abstract

“…The target ULBP1 gene sequence was: upstream, 5′-CACACACTGTCTTTGCTATGAC-3'; downstream, 5′- CCAGGTTTTTGTGACATTGACT-3'. The relative expression level of ULBP1 gene was performed according to previous descript method of 2-∆∆ Cq ( Ruan et al, 2020a ).…”

Section: Methodsmentioning

confidence: 99%

Immune ULBP1 is Elevated in Colon Adenocarcinoma and Predicts Prognosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Colon adenocarcinoma (COAD) is still the main cause of cancer deaths worldwide. Although immunotherapy has made progress in recent years, there is still a need to improve diagnosis, prognosis, and treatment tools. UL-16 binding protein 1 (ULBP1) is a ligand that activates the receptor natural killer cell group 2 receptor D (NKG2D) and plays an important immunomodulatory role. We aimed to investigate the clinical significance of ULBP1 in COAD.Methods: We obtained the relevant data from The Cancer Genome Atlas (TCGA). A total of 438 patients with COAD were included in this study, with a mean age of 67.1 ± 13.03 years old, of which 234 (53.42%) were male. The diagnostic value of COAD tumor tissues and adjacent tissues was analyzed by ROC curve. Univariate and multivariate survival analysis investigated the prognostic value of ULBP1 gene, and Gene Set Enrichment Analysis (GSEA) curve was performed to analyze the biological process and enriched enrichment pathway of ULBP1 in COAD. Combination survival analysis investigated the combined prognostic effect of prognostic genes.Results:ULBP1 gene had a high diagnostic value in COAD [AUC (TCGA) = 0.959; AUC (Guangxi) = 0.898]. Up-regulated ULBP1 gene of patients with COAD predicted a worse prognosis compared to those patients with down-regulated ULBP1 gene (Adjusted HR = 1.544, 95% CI = 1.020–2.337, p = 0.040). The GSEA showed that ULBP1 was involved in the apoptotic pathway and biological process of T cell mediated cytotoxicity, regulation of natural killer cell activation, and T cell mediated immunity of COAD. The combination survival analysis showed that the combination of high expression of ULBP1, AARS1, and DDIT3 would increase the 2.2-fold death risk of COAD when compared with those of low expression genes.Conclusion: The immune-related ULBP1 gene had diagnostic and prognostic value in COAD. The combination of ULBP1, AARS1, and DDIT3 genes could improve the prognostic prediction performance in COAD.

show abstract

<p>The Perspective of Diagnostic and Prognostic Values of Lipoxygenases mRNA Expression in Colon Adenocarcinoma</p>

Cited by 13 publications

References 69 publications

Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report

Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report

A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma

Immune ULBP1 is Elevated in Colon Adenocarcinoma and Predicts Prognosis

Contact Info

Product

Resources

About